Therefore, tamoxifen, an oestrogen receptor (ER) antagonist, sensitised the cells to apoptosis and death [23], in which high HDAC6 in breast cancer is considered to be a better prognostic factor, which correlated with higher disease-free survival rate and better endocrine therapy response [35]. Here, HDAC6 is linked to breast carcinoma.